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Alzheimer’s disease is a proteinopathy characterized by accumulation of hyperphosphorylated Tau and β-amyloid. Autophagy is a
physiological process by which aggregated proteins and damaged organelles are eliminated through lysosomal digestion.
Autophagy deficiency has been demonstrated in Alzheimer’s patients impairing effective elimination of aggregates and damaged
mitochondria, leading to their accumulation, increasing their toxicity and oxidative stress. In the present study, we
demonstrated by microarray analysis the downregulation of fundamental autophagy and mitophagy pathways in Alzheimer’s
patients. The benefits of the Mediterranean diet on Alzheimer’s disease and cognitive impairment are well known, attributing
this effect to several polyphenols, such as oleuropein aglycone (OLE), present in extra virgin olive oil. OLE is able to induce
autophagy, achieving a decrease of aggregated proteins and a reduction of cognitive impairment in vivo. This effect is caused by
the modulation of several pathways including the AMPK/mTOR axis and the activation of autophagy gene expression mediated
by sirtuins and histone acetylation or EB transcription factor. We propose that supplementation of diet with extra virgin olive
oil might have potential benefits for Alzheimer’s patients by the induction of autophagy by OLE.
1. Introduction
1.1. Alzheimer’s Disease. Alzheimer’s disease (AD) is a
progressive, fatal, and currently incurable neurodegenerative
disease. It is clinically characterized by a gradual loss of
cognitive function, including slow deterioration of memory,
reasoning, abstraction, language, and emotional stability
[1]. As a consequence, in the final stages of the disease, the
patient is unable to perform any daily task without adequate
assistance from family members or social services [1]. AD is
the most common cause of dementia worldwide, accounting
for between 50% and 70% of the cases recorded among
people over 65 years old. The aging population presents the
highest risk of the disease, especially in developed countries,
therefore the number of affected people is expected to
increase dramatically up to 115 million in 2050 [2].
The causes of the disease have not been fully clarified,
but several risk factors have been associated with AD.
These are genetic factors (presenilin 1 and 2, apolipopro-
tein Eɛ4 allele), vascular events, history of traumatic brain
injury, oxidative stress, decreased endothelial nitric oxide
production and consequent inflammation, hypertension,
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hyperhomocysteinemia, diabetes, insulin resistance, hyper-
cholesterolemia, obesity, hormonal alterations, lifestyle
factors (saturated fat intake, vitamin E intake, low physical
activity, smoking, etc.), and psychological factors [3].
The main histologic sign confirming the AD diagnosis is
the presence of intracellular neurofibrillary tangles of hyper-
phosphorylated Tau protein and extracellular deposits of
beta-amyloid (Aβ) peptide (senile plaques) in certain areas
of the brain. Tau belongs to the microtubule-associated
proteins (MAPs) family that participates in the assembly
and stabilization of microtubules. This process is necessary
for the maintenance of cellular shape and transport of pro-
teins, organelles, and other biological components through
axons [4]. Additionally, it is important in the connections
between microtubules and other elements of the cytoskeleton
such as neurofilaments, spectrin, or actin filaments [4]. The
Aβ is a peptide that contains between 39 and 43 amino acids,
being a natural product of proteolytic processing of the
amyloid precursor protein (APP), due to the sequential
action of enzymes β- and γ-secretase [5].
For causes not entirely clarified, in AD, both proteins
tend to generate cytotoxic aggregates. These trigger series of
neuronal alterations such as loss of synaptic transmission,
gliosis or proliferation and abnormal activation of glial
cells (astrocytes and microglia) [6], vascular dysfunction
due to fibrillary amyloid deposition at cerebral vessel walls
[7], increased oxidative stress, augmented inflammatory
response, and deregulation of calcium homeostasis [8].
1.2. Autophagy Pathway. Within eukaryotic cells, there are
two systems responsible for the degradation of cytoplasmic
proteins: the ubiquitin-proteasome system (UPS) and the
autophagy. In the case of poorly folded protein aggregates,
it is suggested that autophagy (specifically macroautophagy)
is more efficient in degrading them than UPS. This is due
to the small pore size of proteasomes, which hinders the
entry of proaggregating oligomers and their subsequent
elimination [9].
Autophagy is a process by which the different cellular
components and organelles are transferred to lysosomes
to be degraded by their hydrolytic enzymes [10]. It is a
key process for the correct cell function, acting as a recy-
cling system in energy restriction conditions and allowing
the cell to degrade nonessential organelles and proteins to
reuse their components. In addition, it functions as a
system for eliminating aggregated protein and cytotoxic
damaged organelles [11].
Macroautophagy process (or “autophagy” as we will call
it from now onwards for simplicity) can be divided into three
phases [11]: autophagosome formation, substrate recogni-
tion, and autophagosome trafficking and degradation.
1.2.1. Formation of the Autophagosome. First, cellular
materials to be degraded are isolated into a double membrane
vesicle known as autophagosome. Its formation requires the
fusion of several smaller membranous vesicles to form a
flattened structure called phagophore. This fusion process
continues until the autophagosome with a double membrane
is formed enveloping small fragments of the cytoplasm and
organelles. Initiation of phagosome formation requires acti-
vation of the quaternary complex ULK1-ATG13-ATG101-
FIP200 [12]. This complex is controlled by two signaling
pathways: themTORC1 pathway which acts as an autophagy
blocker by inhibiting ULK1 phosphorylation and the adeno-
sine monophosphate activated protein kinase (AMPK) which
activates ULK1 by phosphorylation of mTORC1 different
residues [13]. Once activated ULK1 phosphorylates and
activates Beclin-1, which in turn triggers the activation of
the VPS34 complex. The latter produces an accumulation
of phosphatidylinositol-3-phosphate (PI3P) in phagophore,
allowing the recruitment of numerous binding proteins
among which the ATG5-ATG12-ATG16L1 complex stands
out. This complex is necessary for phagophore elongation
through the binding to microtubule-associated protein 1
light chain 3 (LC3), which after several conjugations will
result in the active form LC3-II [14]. Finally, the ATG5-
ATG12-ATG16L1 complex is dissociated from the phago-
phore membrane and it ends up closing, creating the
autophagosome and leaving LC3-II associated with the two
faces (external and internal) of autophagosomes [14].
1.2.2. Substrate Recognition and Selective Autophagy. There
are several adaptor proteins that recognize cargo to be
engulfed into autophagosomes such as p62 (sequestosome
1), Next to BRCA1 gene 1 protein (NBR1), Nuclear Domain
10 Protein 52 (NDP52; also known as CALCOCO2), and
optineurin. These proteins recognize substrates specifically
labeled for degradation by ubiquitination, for example, and
bind to LC3 family proteins of phagosome mediating the
recruitment of cargoes [15]. Selective targeting can also
be mediated by autophagy receptors that form a bridge
between the cargo-autophagy receptor complex and com-
ponents of the autophagosome membrane such as ATG5
and PI3P [16]. This is the case of autophagy-linked FYVE
protein (ALFY) that serves as a scaffold protein for p62
mediated labeling [16]. Additionally, BNIP3L is a mito-
chondrial membrane protein containing a LC3-interacting
region motif involved in the targeted clearance of damaged
mitochondria [17].
1.2.3. Autophagosome Trafficking and Degradation. Once the
autophagosome is formed, it is transported by dynein
engines through microtubules to the perinuclear region. In
this pathway, autophagosome may fuse with vesicles from
the endocytic pathway to form amphysomes. Finally, autop-
hagosomes and amphysomes fuse with lysosomes forming
autolysosomes [18]. In them, the degradation of the com-
pounds will be achieved, thanks to the combined action of
acid pH and lysosomal enzymes. The macromolecules
resulting from lysosomal digestion are released to the cytosol
by permeases [19]. Transcription factor EB (TFEB) is as a
master regulator for lysosomal biogenesis, therefore its
activation favors the degradation phase of autophagy [20].
1.3. Autophagy Deficiency in AD. The accumulation of extra-
cellular protein aggregates, mainly composed by polymeric
Aβ42 peptide, a product of proteolysis of APP, is one of the
main responsible for neurological damage and cognitive
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deficit. Under normal conditions, protein aggregates and
damaged organelles are eliminated through autophagy sys-
tem, avoiding their cytotoxic effect. But, as a consequence of
age and oxidative stress, the efficacy of this system is reduced.
This results in the accumulation of poorly digested proteins
in autophagic vacuoles and damaged mitochondria, which
cause an increase in oxidative stress and neuronal death [21].
Several key regulatory proteins in autophagy are reduced
in AD, such as Beclin-1, PARK2/parkin and Nuclear Recep-
tor Binding Factor 2 (NRBF2). Beclin-1 is a fundamental
protein for autophagy regulation and cell death that is found
decreased in brain samples from early-stage Alzheimer’s
patients [22]. In addition, inhibition of Beclin-1 gene expres-
sion in a mice model that expresses human APP produces
intraneuronal accumulation of Aβ, extracellular Aβ depo-
sition, and neurodegeneration [22]. PARK2 is one of the
proteins involved in mitophagy, a specialized form of
autophagy by which mitochondria are selectively degraded
and recycled. PARK2 labels damaged mitochondria for their
subsequent degradation by its E3 ubiquitin ligase activity.
PARK2 is found reduced in the cerebral cortex of AD
patients, leading to a pathological increase of oxidative stress
[23]. NRBF2 is a Beclin-1-Vps34-binding protein that
modulates autophagy via Atg14L-linked Vps34 activity
regulation [24]. NRBF2 expression is found reduced in the
hippocampus of transgenic mice model that reproduces
amyloid pathology characteristic of AD in humans [25].
It has been also proposed that Aβ can cause a patho-
logical accumulation of autophagic vacuoles. Intracellular
Aβ can also modulate the autophagy process by RAGE-
calcium-CaMKKβ-AMPK pathway [26] or by generating
ROS by mitochondrial damage [27].
2. Gene Expression Profiling Demonstrates
Autophagy Dysfunction in AD
In the last years, the advances of high-throughput genomic
analysis have generated data from patients that allow us
the integration of gene deregulations and the determina-
tion of what biological processes are affected in different
pathologies such as neurodegenerations. Particularly in
AD, these gene expression datasets have demonstrated a
significant deregulation of biological processes associated
with calcium signaling, inflammation, and mitochondrial
dysfunction [28]. Several of these processes are known to
have a deep implication in AD pathology. However, these
are not related to one of the main defects associated to
AD, as it is proteotoxicity [28, 29]. Trying to shed light
on this issue, we have analyzed a microarray dataset of brain
samples of AD patients compared to healthy subjects, in
which we focused in protein degradation-associated pro-
cesses. The row data of this microarray dataset were pre-
viously published by the group of Berchtold [30]. Using
gene enrichment analysis of main genes down or upregu-
lated in AD versus healthy with significant differences
(p value <0.01), we analyzed what biological processes
were altered by Gene Ontology. We could observe that
several metabolism and catabolism linked processes such
as mTORC1 pathway, autophagy, and mitophagy were
affected in AD with respect to healthy individuals. These
results are shown in Figure 1, in which the principal modi-
fied genes were represented as well as the gene enrichment
p values for each pathway. Multiple genes from mTORC1
pathway were increased in AD patients which generates an
inhibitory effect over autophagy route, as we mentioned
before. Accordingly, autophagy and mitophagy pathways
were downregulated in these patients’ brain samples. These
effects together determine that the autophagy process was
impaired in AD. Due to the fact that our data is derived from
a large number of patients and different brain zones, this
kind of study by global genomic analysis allows unraveling
how specific biological processes with deep clinic and thera-
peutic involvement are affected. These analyses as well as
multiple other studies that demonstrate an alteration of
metabolic/catabolic pathways that converge in autophagy
deficiency show us an evident necessity to evaluate new
compounds that modulate these routes.
3. Activation of Autophagy as a Therapeutic
Strategy for AD
If the autophagy pathway is altered as part of the pathological
process of AD, autophagy activation may be effective in com-
bating the cellular aggregate characteristic of this pathology.
Numerous studies have shown that the pharmacological
activation of autophagy might be beneficial for AD pathol-
ogy. For example, the effect of 10-week treatment with
rapamycin, an mTOR inhibitor, was studied in a transgenic
mice model that reproduces amyloid and Tau pathology
characteristic of AD in humans. They could achieve a reduc-
tion of Tau and Aβ accumulation as well as cognitive and
memory improvement measured by the spatial reference
version of Morris’s water maze associated to increased
autophagy [31]. However, in a later study, it was demon-
strated that rapamycin accelerated the degeneration of motor
neurons and reduced life expectancy in transgenic mice
models. These results suggested that the pharmacological
activation of rapamycin might affect other pathways that
restricted neuron survival [32].
Other studies have demonstrated the beneficial effect of
promoting autophagy by increasing PARK2 levels. These
works use viral vectors to transfer PARK2 to a triple trans-
genic AD mice model demonstrating the enhancement of
Aβ and phospho-Tau clearance by autophagy activation that
improved mitochondrial function and restored synaptic
function [33, 34]. This mitophagy improvement was further
demonstrated in a human cell model of sporadic AD [23].
On the other hand, the activation of degradation phase of
autophagy has also demonstrated its therapeutic potential in
AD. The deletion of cystatin B, an endogenous inhibitor of
cysteine proteases, to relieve cathepsins inhibition improving
lysosomal function demonstrated to decrease extracellular
amyloid pathology. This change prevented the development
of learning and memory deficits of a transgenic model of
AD (TgCRND8 mice that overexpress APP695 version
including Swe and Ind mutations) [35].
Although the activation of autophagy has demonstrated a
proven effect in the early stages and as a preventive, it is still
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under debate whether this may have poor effect in the
advanced stages of the disease [36].
All these works are the proof of concept that activating
autophagy may be used as a therapeutic approach for AD.
Therefore, it is necessary to find new substances to induce
autophagy minimizing collateral effects.
4. Neuroprotective Role of Mediterranean Diet
and Extra Virgin Olive Oil
Alzheimer’s disease is a multifactorial pathology in which
both genetic and environmental factors are involved,
highlighting among the latter certain aspects of lifestyle
such as nutrition. Diet is a modifiable risk factor for
dementia; thus, increasing efforts have been done to find
nutrients that help to fight cognitive impairment. Some
diets have been associated to reduced risk of AD; there-
fore, they may be helpful to find new compounds that
may be beneficial for AD patients. LipiDiDiet is a research
consortium, which studies the preclinical and clinical
impact of nutrition in Alzheimer’s disease (http://www.
lipididiet.eu/). A recent study has demonstrated that the
multinutrient combination Fortasyn Connect was able to
slow hippocampal atrophy and functional decline by sup-
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Figure 1: Gene expression profiling revealed dysregulation of mTOR, autophagy, and mitophagy pathways in Alzheimer’s disease patients.
Genes having significant differential expression between brain samples from normal controls subjects and AD patients were extracted. The
analysis was done from a microarray dataset having 253 samples from 84 patients (n = 56 normal; n = 28 AD patients [30]). Samples were
collected from four brain regions: hippocampus, entorhinal cortex, superior frontal cortex, postcentral gyrus. Enrichment in pathways and
biological processes of deregulated genes was done using GSEA and Gene Ontology analyses, and the significance of the results (p value)
for each pathway was represented in the graph. We could observe that mTOR pathway was significantly upregulated, whereas autophagy
and mitophagy were significantly downregulated in AD. Genes that exhibited up or downregulation with p value <0.01 using two-tailed
Student’s t-test were selected for representation. Graphs show nodes plots of these altered genes in AD versus controls in each of these
pathways using NetworkAnalyst software (http://www.networkanalyst.ca/faces/home.xhtml).
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The Mediterranean diet (MD) has already demonstrated
on multiple occasions its beneficial effects in preventing age-
specific defects, including attenuating and preventing AD
and cognitive impairment [38, 39]. For example, the 4-year
study in a population of 2258 New York City residents found
that increased adherence to MD reduced the risk of develop-
ing AD and was especially effective in preventing the
conversion of mild cognitive impairment to AD [40]. This
study showed that individuals with high adherence to MD
had a 40% lower risk of developing AD and a 48% lower risk
of progressing from mild cognitive impairment to AD [40].
In another study using a population of 1410 Bordeaux
citizens over 65 years of age, high adherence to MD was
associated with a reduction of cognitive impairment demon-
strated by the Mini-Mental State Examination [41].
This neuroprotective effect has been associated with
several foods found in MD, including wine and extra virgin
olive oil (EVOO) standing out, the latter being one of the
most internationally recognized due to its multiple beneficial
properties. Among them, it is worth mentioning its role as a
mental health promoter and in slowing cognitive decline in
neurodegenerative diseases in the elderly population. This
was demonstrated by the “three-cities study” on an elderly
population of more than 8000 subjects, being the first report
relating olive oil consumption with lower reduction of visual
memory in a population over 65 years old [42].
Similar beneficial effect has been observed in both in vitro
and in vivo studies where supplementation with EVOO is
able to reduce the advance of Tau and Aβ pathology and
cognitive deterioration [43–45]. The most recent study
concludes that consumption of EVOO in early ages and for
a long time could provide a protective effect against AD
pathology and cognitive deterioration [45].
Several studies in animal models have shown that this
beneficial action is due to a series of substances known
as polyphenols [46], including oleuropein aglycone (OLE)
present in EVOO [47].
5. Oleuropein Aglycone as
an Autophagy Inducer
5.1. Polyphenols and Autophagy. Since the discovery of the
benefits of moderate wine consumption for the prevention
of dementia thanks to the presence of a substance called
resveratrol (and not alcohol as initially suggested), numerous
studies have attributed the beneficial effects of polyphenols
on health. They are considered the substances responsible
for the multiple mental health benefits attributed to the
Mediterranean and Oriental diet [48].
Polyphenols are an extensive group of nonenergetic
substances present in plant-based foods characterized by
the presence of one or more phenolic rings. They can be
classified according to their number of phenolic rings and
the structural elements present these rings. The main groups
are phenolic acids (derived from hydroxybenzoic acid or
hydroxycinnamic acid), stilbenes, lignans, phenolic alcohols,
and flavonoids [49].
An interesting fact showed by the different studies is that
polyphenols do not act in a single pathway or modulating a
certain aspect of AD, such as inhibition of Aβ aggregation.
Their neuroprotective function comes from the modulation
of different cellular and tissue processes that together are
responsible for the reduction of cognitive impairment
[35]. The Aβ toxic aggregates inhibition and the decrease
in ROS produced by mitochondria and neuroinflammation
are the main positive effects of polyphenols. But some of
these effects may be in part due to another not so well
studied action of these substances, and that is the induction
of autophagy [50].
As we have previously described, autophagy plays a
crucial role in AD, whose alterations have been considered
preclinical events to pathology. In addition, induction of this
process has proven to be a promising target for pharmacolog-
ical action. Hence, it would be very helpful to look for new
substances that have a positive effect on this detoxification
system, and this is where polyphenols come in.
There are multiple pathways by which polyphenols can
modulate autophagy, and not all of them act through the
same route. See Hasima and Ozpolat [51] for a summary of
involved pathways.
Polyphenols are able to modulate autophagy through
canonical (Beclin-1 dependent) and noncanonical (Beclin-1
independent) signaling pathways. In the canonical pathway,
Beclin-1 together with the regulatory subunits Vps34 and
Vps15 form a protein complex known as Class III phos-
phatidylinositol 3-kinase (PI3K), inducing autophagy by
modulating the autophagosomal nucleation. While in nonca-
nonical or Beclin-1 independent, two activation mechanisms
can be given, Atg5/Atg7 dependent or independent [51, 52].
For example, genistein is able to induce PI3K/Akt-
dependent autophagy by reducing Akt phosphorylation
levels, leading to autophagy induction as a false signal of cal-
orie restriction [53]. Curcumin performs its function through
inhibition of Akt/mTOR/p70S6K protein complex and Erk1/
2 protein kinase activation, demonstrating an increase of
autophagy in glioblastoma cells [54]. Rottlerin, a polyphenol
extracted from the Asian Mallotus philippensis tree, has
demonstrated its effect as an autophagy inducer through its
antioxidant function. Rottlerin blocks the generation of free
radicals and triggers inhibition of NF-κB and activation of
AMPK, which is associated with a decrease of ATP levels.
The cell translates this ATP drop as a state of caloric restric-
tion, so it activates autophagy as a regulatory mechanism
[55]. Rottlerin is also able to activate autophagy through
inhibition of PKCδ, a protein kinase that blocks autophagy
through activation of tissue transglutaminase 2 (TG2) [56].
One of the most studied mechanisms of action of
polyphenols is through sirtuins, a group of deacetylases that
regulate cellular functions as important as metabolism,
immunity, inflammation, and cell survival. Sirtuins act as
modulators of autophagy both directly by promoting the
deacetylation of key components such as autophagic gene
products Atg5, Atg7, and Atg8 and indirectly by regulating
FOXO3a transcription factor [52]. Once activated, FOXO3a
induces autophagy by synthesis of glutamine synthetase, an
enzyme that increases glutamine levels. This increase in
glutamine causes inhibition of mTOR and the consequent
activation of autophagy [57]. Resveratrol, genistein, and
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quercitin have been shown to be promising activators of
sirtuins [38, 52].
5.2. Mechanisms of Autophagy Induction by Oleuropein
Aglycone. One of the polyphenols better characterized as an
autophagy inducer is oleuropein aglycone (OLE), which is
found in EVOO. Oleuropein is a secoiridoid glycoside with
a phenylpropanoid alcohol obtained from the biosynthesis
of mevalonic acid. From the chemical point of view, it is an
11-methyl-ester (elenolic acid glucoside) ester combined
with 3,4-dihydroxyphenylethanol (3,4-DHPEA). It is the
major phenolic component of the pulp of the green olives
and leaves of the Gentianaceae, Cornaceae, and Oleaceae
families, in the latter family being especially relevant in the
variety Olea europaea L. (which gives its name to the
glycoside) [58]. After the process of maturation and extrac-
tion of the olive juice, in the EVOO, due to the action of
the enzyme β-glucosidase, we can only find this secoiridoid
in its aglyconic form as OLE (3,4-DHPEA-EA), being
aldehydic form of OLE, the main responsible for its bitter
taste [59, 60]. The relative amount of OLE in EVOO depends
on the variety of olive fruit used, being in many of them one
of the most abundant polyphenols [61].
Several in vitro and in vivo studies have demonstrated the
multiple benefits of oleuropein and its derivatives associated
to their antioxidant, antidiabetic, antimicrobial, antiviral,
antitumor, hepatoprotective, cardioprotective, neuroprotec-
tive, antiaging, and anti-inflammatory properties [62–65].
In terms of neuroprotective activity, the most recent exper-
imental studies have shown that OLE reduces cognitive
impairment and improves synaptic function in animal
models. This is due to the inhibition of the aggregation
and toxicity of Tau [66] and Aβ [67], the epigenetic modula-
tion by histone acetylation [68], the reduction of astrocytosis
and modulation of astroglia activity, and the induction of
autophagy [69].
The effects of OLE on Tau aggregation was demonstrated
by studying the antiaggregant capacity of oleuropein and its
derivatives (OLE and hydroxytyrosol) over wild-type and
P301L Tau protein in vitro. They were able to obtain results
similar to methylene blue in inhibiting fibrillization at
low micromolar concentrations of Tau, demonstrating a
higher inhibitory capacity of OLE related to the presence
of aldehyde groups in its structure [66]. A posterior study
demonstrated the inhibition of Aβ aggregation using the
transgenic strain CL2006 of Caenorhabditis elegans, a sim-
plified model of AD expressing human Aβ peptide in the
cytoplasm of muscle cells of the body wall. They found
that larvae fed with OLE showed a reduction of Aβ plaque
deposits, a lower content of toxic Aβ oligomers, a marked
decrease of paralysis, and an increase of life expectancy
with respect to untreated animals [67].
On the other hand, several reports have associated the
effect of OLE to a positive modulation of autophagy pathway
that leads to cognitive improvement in animal models. One
of the first works that demonstrated this hypothesis was the
study carried out by Grossi and collaborators using wild-
type and TgCRND8 transgenic mice, as mentioned before,
a model for human Aβ pathology [35, 70]. In this study, mice
whose diet was supplemented with OLE (50mg/kg of food)
exhibited an increase of autophagic vesicles. This was
demonstrated by the augmented levels of Beclin-1 and LC3
in the soma and dendrites of neurons from different parts
of the somatosensory/parietal and entorhinal/piriform
cerebral cortex correlating with increased LC3II/LC3I ratio.
This induction was more significant in TgCRND8 transgenic
mice rather than in wild-type. Additionally, these authors
demonstrated that OLE improved the autophagosome-
lysosome fusion measured as the increase of p62 and cathep-
sin B levels in OLE supplemented TgCRND8 mice up to the
levels found in wild-type mice. They also reported the coloca-
lization of both p62 and cathepsin B labels suggesting a
proper fusion of lysosomes to autophagic vesicles and,
therefore, functional degradation phase of autophagy. They
proposed that the mechanism of autophagy activation might
be due to the inhibition of mTOR pathway reflected in the
decrease of phosphorylation of its target p70S6 protein
kinase in cell culture.
5.2.1. OLE as Modulator of Ca+2-CaMKK-AMPK-mTOR
Axis. Initially, it was proposed that the mechanism by which
OLE induced autophagy would be through the increase of
cytosolic levels of Ca+2 and the subsequent activation of
the enzyme complex AMPK through Ca2+/Calmodulin
Protein Kinase Kinase β (CaMKKβ). This complex facili-
tates mTORC1 inhibition and ULK1 activation to generate
autophagic vacuole induction [71] (Figure 2). This is also the
case of other polyphenols such as resveratrol [72] and epi-
gallocatechin gallate (EGCG) [73]. Accordingly, they demon-
strated a biphasic phosphorylation of the regulatory residue
Thr172 of AMPK correlating with elevated Beclin-1 levels
in SH-SY5Y cells treated with 50μM OLE [71]. This was
mediated by the biphasic increase of intracellular Ca2+ levels
that come from the endoplasmic reticulum that induce
CaMKKβ activation. This correlates with a fast increase of
Beclin-1 levels that was proposed to arise from the Beclin-1
fraction complexed with Bcl-2/Bcl-xL in the cytoplasm
rather than to new synthesis. The release of Beclin-1 from
this complex is critical for inducing autophagy because free
Beclin-1 interaction with VPS34 is needed to initiate autop-
hagosome formation [74]. The activation of autophagy by
OLE was partially inhibited by STO-609 and component C,
inhibitors of CaMKKβ and AMPK, respectively, suggesting
that autophagy activation by OLE occurs mainly through
the Ca2+ increase that induces CaMKKβ activation and the
subsequent AMPK phosphorylation [71].
All these results together indicate that OLE activates
AMPK, which can allow the formation of ULK1 quaternary
complex directly or indirectly by the inhibition of mTOR
that inhibits ULK1 (Figure 2). ULK1 promotes autophagy
by Beclin-1 phosphorylation and VPS34 lipid kinase acti-
vation that produces phosphatidylinositol 3-phosphate,
necessary for the formation of the early autophagosomal
membrane [75].
5.2.2. OLE as Modulator of PARP1-SIRT1 Axis. Multiple
polyphenols are known to induce autophagy by the acti-
vation of sirtuins (SIRT) [52]. SIRT1 deacetylates many
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transcription factors such as p53, NF-κB, and FOXO, a medi-
ator of autophagy. SIRT1 could influence autophagy directly
via deacetylation of key components of the autophagy induc-
tion network, such as the products of autophagy genes Atg5,
Atg7, and Atg8 [76]. The treatment of TgCRND8 mice with
OLE (50mg/Kg of diet) was able to reduce the activation of
Poly (ADP-ribose) polymerase-1 (PARP1) at both RNA
and protein levels as well as the subsequent accumulation
of PAR polymers up to the levels found in wild-type mice
[77]. Moreover, OLE was able to abolish the increase of
the apoptotic mediators phospho-NF-κB and phospho-p53
Ser46 in these animals. PARP1 activation causes a reduction
of NAD+ levels that result in SIRT1 inhibition [78]. There-
fore, OLE-mediated reduction of PARP1 increased NAD+
levels that were able to induce SIRT1 in TgCRND8 mice
[77] (Figure 2). Accordingly, the treatment of N2a cells
with OLE 100μM for 24 h was able to reverse the PARP1
activation caused by methylnitronitrosoguanidine (MNNG),
a mutagen that activates PARP1 expression, as well as
increased SIRT1 and Beclin-1 [77].
5.2.3. OLE as Epigenetic Modulator. It is also worth mention-
ing the action of OLE as an epigenetic modulator. It is known
that abnormal acetylation takes place in memory and
learning disorders such as AD, where significant increase of
histone deacetylase 2 (HDAC2) inhibits gene expression of
specific locus, such as autophagy markers [79]. Moreover,
histone acetylation has been shown to ameliorate cognitive
deficits in AD animal models suggesting its targeting as a
promising therapeutic strategy for this disease [79]. Polyphe-
nols have shown to regulate gene expression by modulating
histone acetylation and DNA methylation, as is the case of
EGCG in cancer cells [80].
Noteworthy, TgCRND8 mice showed increased levels of
HDAC2 correlating with decreased levels of histone 3
acetylation on lysine 9 (H3K9) and of histone 4 acetylation
on lysine 5 (H4K5) in cortex and hippocampus [68]. The
treatment with OLE (50mg/kg of diet for 8 weeks) signifi-
cantly decreased the levels of HDAC2 in both wild-type
and TgCRND8 mice and increased H3K9 and H4K5 espe-
cially in the transgenic model (Figure 2). This was accom-
panied by an improvement of synaptic function revealed
by restoring high-frequency stimulation-induced long-term
potentiation as well as 3-theta burst and high-frequency
stimulation-evoked posttetanic potentiation in slices of
brains of OLE-treated transgenic mice.
On the other hand, transcription factor EB (TFEB) is
a master regulator of lysosomal and autophagic function
[81, 82]. Previous studies demonstrated that mTOR-
mediated phosphorylation of TFEB in Ser 211 promotes the
interaction of TFEB with the 14-3-3 protein and results in a
cytoplasmic localization, therefore inhibiting its function as
a transcriptional factor [83] (Figure 2). It has been recently
shown that activation of calcineurin by lysosomal Ca2+
releases binds and dephosphorylates TFEB, thus promoting
its nuclear translocation inducing autophagy and lysosomal
biogenesis [84]. As we previously mentioned, OLE was able
to increase intracellular Ca2+ that activates Ca2+/CaMKKβ/
AMPK axis [71]. Hence, Ca2+ release coming from different
organelles might induce autophagic flux independently
but possibly, synergistically. Further studies will be neces-
sary to unravel if intracellular Ca2+ increase mediated by
OLE is able to activate calcineurin and the subsequent
TFEB dephosphorylation and activation which induce
autophagy (Figure 2).
6. Bioavailability and Effective Dose of OLE
Before presuming an effect of OLE in neurons in humans, it

















































Figure 2: Pleiotropic action of OLE over autophagy induction. Summary of autophagy pathways in which OLE has demonstrated an effect.
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ingested and if it arrives in its full form or with modifications.
In humans, it has been demonstrated that the apparent
absorption of olive oil phenols, among which is OLE, ranges
between 55 and 66% of the ingested dose [85]. This is
performed mainly in the small intestine and in a minor pro-
portion in the colon and, once in the blood, the oleuropein is
transported by lipoproteins where it is rapidly distributed
[85, 86] (Figure 2). The mechanism of OLE absorption is still
unknown, as well as those of other olive oil polyphenols [87].
However, it is known that intestinal absorption and renal
clearance of oleuropein and hydroxytyrosol are relatively
rapid, reaching their maximum plasma concentration at half
an hour after ingestion, followed by a rapid decline culminat-
ing in 2.5 hours [86]. The main metabolites that can be found
in plasma and urine after oleuropein ingestion are hydroxy-
tyrosol and its conjugates (sulfated and glucuronidated)
followed by OLE [86]. In addition, there is a strong individual
component regarding the bioavailability and metabolism of
oleuropein depending on the gender, being men the most
efficient in conjugating this substance, which explains the
lower plasma levels compared to the increased levels of
conjugated forms of hydroxytyrosol [86]. On the other hand,
the absorption of oleuropein is much more efficient if the
compound is taken in liquid form rather than ingestion in
capsules [86].
In addition, it has been suggested that OLE, being one of
the less polar compounds of the olive oil polyphenols, is
mostly transformed in hydroxytyrosol either in the gastroin-
testinal tract before it is absorbed or in the intestinal cells,
blood, or liver after its absorption [85]. Nonetheless, it has
been recently demonstrated that hydroxytyrosol is able to
induce autophagy in chondrocytes after oxidative stress
exposure mainly, but not exclusively, by SIRT1 induction
[88]. This opens the possibility that not only OLE but also
its derivatives are able to induce the protective autophagy
induction described in this review.
The autophagy induction by OLE can occur even at
low doses. It was demonstrated that high concentrations
(50mg/kg) of a mixture of polyphenols present in olive
mill waste water (among which was OLE), as well as
medium (12.5mg/kg) and low concentrations (0.5mg/kg)
of OLE increased autophagic activity in the cortex of
TgCRND8 mice [89]. They could also observe that
12.5mg/kg of OLE or 50mg/kg of polyphenols mix sig-
nificantly improved cognitive functions and diminished
Aβ deposition of TgCRND8 mice.
Considering a variety of EVOO specially enriched in
OLE as is Seggianese oil, an Italian olive oil whose OLE
content is above 30% of total secoiridoids of which are
ranging 619± 128mg/L [90], the amount of OLE is over
185.7mg/L in this EVOO variety. The daily recommendation
of EVOO consumption in theMediterranean diet is 25–50ml
[91] that would represent between 4.6 and 9.3mg of OLE
using Seggianese oil. Taking into consideration the differ-
ences of weight between mice (20 g) and humans (e.g.,
60Kg), the daily concentration of OLE would be the equiva-
lent to 1.5–3.1μg/day in mice. The OLE daily intake at which
autophagy induction was achieved in the study by Pantano
et al. was 0.5mg/kg of food [89]. Considering that mice
model eats 3–5 g/day (http://www.researchdiets.com), this
would correspond to a dose of 1.5–2.5μg/day of OLE. As
we calculated before, this amount of OLE was equivalent to
the daily intake of Seggianese oil. The minimum dose in the
study by Pantano et al. that achieved functional recovery
and reduced amyloid beta burden was 12.5mg/Kg of food
[89] that would correspond to 37.5–62.5μg/day of OLE. This
amount exceeds the OLE quantity guaranteed by the daily
intake of EVOO and this may indicate that the effect of
EVOO might not be enough in advanced stages of the
disease. However, EVOO contains many other components
with potential beneficial effects over health and cognitive
improvement apart from OLE. Therefore, further studies
are necessary to determine the minimum active dose of
OLE and the potential benefit of EVOO intake.
In addition, administration of 50mg/Kg OLE in the diet
was safe and none of the TgCRND8 mice involved in the
experiment died or suffered any side effects due to high
intake of OLE [70]. Moreover, the presence of several foods
with substantial levels of polyphenols is one of the main
explanations for the healthy properties of the Mediterranean
and Asian diets [92, 93]. Taking in consideration all these
studies, we can deduce that high doses of polyphenols
might not be harmful to humans. However, specific studies
of OLE intake in humans are necessary to rule out its
possible toxicity.
Many open questions remain regarding the action of
OLE once ingested and whether it is able to reach the neu-
rons and exert its function. Furthermore, the determination
of these metabolites’ bioactivity and the levels at which
OLE can become toxic needs to be analyzed. Regarding the
possible effect of OLE in humans, further studies are neces-
sary to determine OLE stability in human gastric fluids and
blood. Additionally, it is important to unravel whether OLE
is absorbed and is able to cross the blood-brain barrier
unmodified. One important limitation for these studies is
that purified OLE is not available for human consumption
so far. Notwithstanding, there are many ongoing studies that
analyze the beneficial effects of EVOO consumption in
humans; from those, it might be possible to extrapolate
conclusions about OLE effect. With this aim, it will be neces-
sary to determine the exact concentration of OLE in a
concrete EVOO variety and supplement volunteers with an
exact daily dose. This would allow to estimate the concentra-
tion of OLE and its derivatives in blood and cerebrospinal
fluid. However, being EVOO amixture of many polyphenols,
which most of them generate similar derivatives, this deter-
mination might be inexact. Moreover, as several polyphenols
and derivatives may have similar beneficial effects on health,
it would be difficult to attribute this outcome to one single
compound. It is mandatory to clarify if the autophagy
induction mediated by OLE depends on its unmodified form
or on its conversion in hydroxytyrosol. This issue would be
easier to achieve in vitro by studying autophagy induction
after treatment of human cells, such as SH-SY5Y, with equiv-
alent doses of OLE or hydroxytyrosol and evaluating their
stability during experimental conditions.
Finally, unless we could acquire purified OLE for human
consumption, the conclusions obtained from these studies
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will be merely speculative and should be carefully supported
by equivalent experiments in animals where purified OLE
and EVOO can be compared.
In summary, the cognitive improvement developed in
animal models of Alzheimer’s disease, such as TgCRND8
mice [70], indicates that supplementation of the diet with
OLE may have beneficial effects in slowing cognitive decline
in these patients. This clearly indicates that either directly
OLE or its derivatives are able to cross the blood-brain
barrier and develop their neuroprotective function in the
brain, where a decrease in protein aggregates and a signifi-
cant activation of autophagy were observed.
7. Conclusions
Polyphenols are known to be the substances responsible
for the neuroprotective properties attributed to the Asian
and Mediterranean diets, rich in foods that contain a large
amount of these compounds of plant origin [50]. We have
focused our attention in OLE, one of the polyphenols
abundant in EVOO and one of the bases of the Mediterra-
nean diet [94].
In the present work, we have summarized all the
works that have demonstrated that OLE reduced symp-
toms of AD and cognitive impairment [68, 70, 71, 89].
Several studies have proposed that OLE mechanism of
action associated to this cognitive improvement was by
autophagy induction that has been also shown to reduce
amyloid aggregates [50, 68–71, 77, 89]. Furthermore, OLE
does not show side effect (cell death or apoptosis), as is the
case of some polyphenols such as curcumin [48], nor neuro-
degeneration as is the case of prolonged treatment with
rapamycin [32]. This, together with its ability to fight cyto-
toxicity derived from the accumulation of Aβ and reduce
inflammation derived from the activation of astrocytes and
microglia are responsible for the decrease in cognitive
impairment in TgCRND8 mice. Unfortunately, there are no
evidences of OLE benefits in humans due to the complexity
of these studies. But extrapolating the results of the studies
that related adherence to the Mediterranean diet [40] or olive
oil consumption [42] with the decrease in the prevalence of
neurodegenerative diseases, the cognitive improvement in
AD mice model [70] and the results in human SH-SY5Y
neuroblastoma cells [71], we can conclude that OLE con-
sumption might be useful for delaying cognitive impairment
in humans.
The data presented in our study confirm that OLE is a
compound capable of inducing autophagy in both in vitro
and in vivo models and that this leads to an improvement
in cognitive impairment as well as in β amyloid and Tau
aggregation. Therefore, based on studies on the consumption
of EVOO and adherence to the Mediterranean diet, rich in
polyphenols including OLE, we can hypothesize OLE would
be useful to prevent and lessen symptoms associated with
AD. However, more studies are needed to test the effects of
OLE in humans, in terms of metabolic pathways and
bioavailability, as well as to demonstrate the effects of OLE
on gene expression.
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